Psychopharmacology

, Volume 219, Issue 4, pp 1133–1140 | Cite as

Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders

  • Elen V. Fagherazzi
  • Vanessa A. Garcia
  • Natasha Maurmann
  • Thielly Bervanger
  • Luis H. Halmenschlager
  • Stefano B. Busato
  • Jaime E. Hallak
  • Antônio W. Zuardi
  • José A. Crippa
  • Nadja Schröder
Original Investigation

Abstract

Rationale

Cannabidiol, the main nonpsychotropic constituent of Cannabis sativa, possesses a large number of pharmacological effects including anticonvulsive, sedative, hypnotic, anxiolytic, antipsychotic, anti-inflammatory, and neuroprotective, as demonstrated in clinical and preclinical studies. Many neurodegenerative disorders involve cognitive deficits, and this has led to interest in whether cannabidiol could be useful in the treatment of memory impairment associated to these diseases.

Objectives

We used an animal model of cognitive impairment induced by iron overload in order to test the effects of cannabidiol in memory-impaired rats.

Methods

Rats received vehicle or iron at postnatal days 12–14. At the age of 2 months, they received an acute intraperitoneal injection of vehicle or cannabidiol (5.0 or 10.0 mg/kg) immediately after the training session of the novel object recognition task. In order to investigate the effects of chronic cannabidiol, iron-treated rats received daily intraperitoneal injections of cannabidiol for 14 days. Twenty-four hours after the last injection, they were submitted to object recognition training. Retention tests were performed 24 h after training.

Results

A single acute injection of cannabidiol at the highest dose was able to recover memory in iron-treated rats. Chronic cannabidiol improved recognition memory in iron-treated rats. Acute or chronic cannabidiol does not affect memory in control rats.

Conclusions

The present findings provide evidence suggesting the potential use of cannabidiol for the treatment of cognitive decline associated with neurodegenerative disorders. Further studies, including clinical trials, are warranted to determine the usefulness of cannabidiol in humans suffering from neurodegenerative disorders.

Keywords

Cannabidiol Memory Neurodegenerative disorders Neuroprotection Iron 

Notes

Acknowledgments

This research was supported by the National Council for Scientific and Technological Development (CNPq; grant number 305905/2009-0 to N.S.), and the National Institute for Translational Medicine (INCT-TM). JASC, JECH, AWZ, and NS are recipients of the CNPq fellowship research awards. TB is a recipient of the FAPERGS fellowship.

References

  1. Avraham Y, Grigoriadis NC, Poutahidis T, Vorobiev L, Magen I, Ilan Y, Mechoulam R, Berry E (2010) Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. Br J Pharmacol 162:1650–1658CrossRefGoogle Scholar
  2. Cassol-Jr OJ, Comim CM, Silva BR, Hermani FV, Constantino LS, Felisberto F, Petronilho F, Hallak JE, De Martinis BS, Zuardi AW, Crippa JA, Quevedo J, Dal-Pizzol F (2010) Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture. Brain Res 1348:128–138PubMedCrossRefGoogle Scholar
  3. Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez-Orgado J (2010) The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 37:434–440PubMedCrossRefGoogle Scholar
  4. Crippa JA, Zuardi AW, Hallak JE (2010) Therapeutical use of the cannabinoids in psychiatry. Rev Bras Psiquiatr 32(Suppl 1):S56–S66PubMedGoogle Scholar
  5. Dal-Pizzol F, Klamt F, Frota ML Jr, Andrades ME, Caregnato FF, Vianna MM, Schröder N, Quevedo J, Izquierdo I, Archer T, Moreira JC (2001) Neonatal iron exposure induces oxidative stress in adult Wistar rat. Brain Res Dev Brain Res 130:109–114PubMedCrossRefGoogle Scholar
  6. de Lima MN, Polydoro M, Laranja DC, Bonatto F, Bromberg E, Moreira JC, Dal-Pizzol F, Schröder N (2005a) Recognition memory impairment and brain oxidative stress induced by postnatal iron administration. Eur J Neurosci 21:2521–2528PubMedCrossRefGoogle Scholar
  7. de Lima MN, Laranja DC, Caldana F, Bromberg E, Roesler R, Schröder N (2005b) Reversal of age-related deficits in object recognition memory in rats with l-deprenyl. Exp Gerontol 40:506–511PubMedCrossRefGoogle Scholar
  8. de Lima MN, Dias CP, Torres JP, Dornelles A, Garcia VA, Scalco FS, Guimarães MR, Petry RC, Bromberg E, Constantino L, Budni P, Dal-Pizzol F, Schröder N (2008) Reversion of age-related recognition memory impairment by iron chelation in rats. Neurobiol Aging 29:1052–1059PubMedCrossRefGoogle Scholar
  9. Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G, Mann K, Hermann D (2011) Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend 114:242–245PubMedGoogle Scholar
  10. Ding B, Chen KM, Ling HW, Sun F, Li X, Wan T, Chai WM, Zhang H, Zhan Y, Guan YJ (2009) Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease. J Magn Reson Imaging 29:793–798PubMedCrossRefGoogle Scholar
  11. Dirikoc S, Priola SA, Marella M, Zsürger N, Chabry J (2007) Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J Neurosci 27:9537–9544PubMedCrossRefGoogle Scholar
  12. El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai NJ, Roon P, Caldwell RB, Caldwell RW, Green K, Liou GI (2003) Neuroprotective effect of (−)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-d-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol 163:1997–2008PubMedCrossRefGoogle Scholar
  13. Esposito G, Scuderi C, Savani C, Steardo L Jr, De Filippis D, Cottone P, Iuvone T, Cuomo V, Steardo L (2007) Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 151:1272–1279PubMedCrossRefGoogle Scholar
  14. Fernandez LL, de Lima MN, Scalco F, Vedana G, Miwa C, Hilbig A, Vianna M, Schröder N (2011) Early post-natal iron administration induces astroglial response in the brain of adult and aged rats. Neurotox Res 20:193–199PubMedCrossRefGoogle Scholar
  15. García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J (2007) Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134:162–170PubMedCrossRefGoogle Scholar
  16. Hampson AJ, Grimaldi M, Alexrod J, Wink D (1998) Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268–8273PubMedCrossRefGoogle Scholar
  17. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 89:134–141PubMedCrossRefGoogle Scholar
  18. Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L (2009) Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 15:65–75Google Scholar
  19. Izquierdo I, Medina JH (1997) Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures. Neurobiol Learn Mem 68:285–316PubMedCrossRefGoogle Scholar
  20. Kell DB (2010) Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 84:825–889PubMedCrossRefGoogle Scholar
  21. Krishnan S, Cairns R, Howard R (2009) Cannabidiol for the treatment of dementia. Cochrane Database Syst Rev 2:CD007204Google Scholar
  22. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19:96–107PubMedCrossRefGoogle Scholar
  23. Lavados M, Guillón M, Mujica MC, Rojo LE, Fuentes P, Maccioni RB (2008) Mild cognitive impairment and Alzheimer patients display different levels of redox-active CSF iron. J Alzheimers Dis 13:225–232PubMedGoogle Scholar
  24. Lichtman AH, Dimen KR, Martin BR (1995) Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) 119:282–290CrossRefGoogle Scholar
  25. Miwa CP, de Lima MN, Scalco F, Vedana G, Mattos R, Fernandez LL, Hilbig A, Schröder N, Vianna MR (2011) Neonatal iron treatment increases apoptotic markers in hippocampal and cortical areas of adult rats. Neurotox Res 19:527–535PubMedCrossRefGoogle Scholar
  26. Morgan CJ, Schafer G, Freeman TP, Curran HV (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 197:285–290PubMedCrossRefGoogle Scholar
  27. Perez VP, de Lima MN, da Silva RS, Dornelles AS, Vedana G, Bogo MR, Bonan CD, Schröder N (2010) Iron leads to memory impairment that is associated with a decrease in acetylcholinesterase pathways. Curr Neurovasc Res 7:15–22PubMedCrossRefGoogle Scholar
  28. Rech RL, de Lima MN, Dornelles A, Garcia VA, Alcalde LA, Vedana G, Schröder N (2010) Reversal of age-associated memory impairment by rosuvastatin in rats. Exp Gerontol 45:351–356PubMedCrossRefGoogle Scholar
  29. Schröder N, Fredriksson A, Vianna MR, Roesler R, Izquierdo I, Archer T (2001) Memory deficits in adult rats following postnatal iron administration. Behav Brain Res 124:77–85PubMedCrossRefGoogle Scholar
  30. Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009) Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res 23:597–602PubMedCrossRefGoogle Scholar
  31. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5(11):863–873PubMedCrossRefGoogle Scholar
  32. Zuardi AW (2008) Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30:271–280PubMedCrossRefGoogle Scholar
  33. Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, Dursun SM, Tumas V (2009) Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 23:979–983PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Elen V. Fagherazzi
    • 1
    • 2
  • Vanessa A. Garcia
    • 1
    • 2
  • Natasha Maurmann
    • 1
    • 2
  • Thielly Bervanger
    • 1
  • Luis H. Halmenschlager
    • 1
    • 2
  • Stefano B. Busato
    • 1
  • Jaime E. Hallak
    • 2
    • 3
  • Antônio W. Zuardi
    • 2
    • 3
  • José A. Crippa
    • 2
    • 3
  • Nadja Schröder
    • 1
    • 2
    • 4
  1. 1.Neurobiology and Developmental Biology Laboratory, Faculty of BiosciencesPontifical Catholic UniversityPorto AlegreBrazil
  2. 2.National Institute for Translational Medicine (INCT-TM)Porto AlegreBrazil
  3. 3.Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão PretoUniversidade de São PauloRibeirão PretoBrazil
  4. 4.Department of Physiological Sciences, Faculty of BiosciencesPontifical Catholic UniversityPorto AlegreBrazil

Personalised recommendations